Jefferies Maintains Buy Rating and $50 PT on Questcor Pharmaceuticals

A report from Jefferies reiterates its Buy rating and $50 price target on Questcor Pharmaceuticals QCOR. The report states, “We had an opportunity to host investor meetings with Questcor management, and are confident mgmt will continue to execute in the last 6 weeks of 2011, and into 2012. One of the leading indicators that sales have not peaked is mgmt intention to expand both the MS and nephrology sales forces in 2012. If the short-term decline in MS prescriptions for October (vs Sept) were durable, we believe mgmt would not be discussing these plans.” QCOR closed yesterday at $43.63.